Skip to content

Preimplantation Genetic Testing in Women of Advanced Maternal Age

GEnetic Testing in Elective Single Embryo Transfer in Women of Advanced Maternal Age

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04167748
Acronym
GETSET
Enrollment
240
Registered
2019-11-19
Start date
2021-03-05
Completion date
2026-12-31
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

Detailed description

In this randomized controlled trial, a total of 240 patients divided evenly across the two participating IVF centers will be recruited. Patients will be randomized to a control and to a treatment group, each containing 120 participants. Only patients with at least one evaluable blastocyst will be randomized. Patients will undergo ovarian hyper-stimulation, oocyte retrieval, fertilization and embryo culture per standard clinical protocol determined by IVF center. In the control arm, patients will undergo a single frozen embryo transfer with an untested blastocyst with the best morphology. All other blastocysts with lower morphology will undergo trophectoderm biopsy on day 5, 6 or 7 and will be frozen. PGT-A results of the untransferred embryos will be revealed to the patient AFTER the outcome of the initial ET is known. If the initial transfer results in a non-conception cycle and additional euploid embryos are available for transfer, these cycles will be followed and their outcomes collected. In the experimental arm, all embryos will be cultured to blastocyst and all viable blastocysts will undergo trophectoderm biopsy and PGT-A. PGT-A will be performed regardless of the number of blastocysts available. Patients will undergo frozen transfer of the single, best quality euploid blastocyst. If the initial transfer results in a non-conception cycle and additional embryos are available for transfer, these cycles will be followed and their outcomes collected until the embryo cohort is exhausted.

Interventions

PROCEDUREPreimplantation genetic testing for aneuploidy (PGT-A)

24-chromosome screening for aneuploidy in the preimplantation embryo (blastocyst stage)

Sponsors

Genomic Prediction Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Allocation information will be handled by researcher coordinators only.

Intervention model description

Prospective randomized clinical trial

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols

Exclusion criteria

* Patients with anovulatory Polycystic ovarian syndrome (PCOS) * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers

Design outcomes

Primary

MeasureTime frameDescription
Ongoing pregnancy rateUp to 18 monthsNumber of patients who experience an ongoing pregnancy rate (\>20 weeks of gestation) after their first embryo transfer

Secondary

MeasureTime frameDescription
Miscarriage rateUp to 18 monthsNumber of patients who experience a miscarriage after their first embryo transfer

Countries

United States

Contacts

Primary ContactNathan R Treff, PhD
nathan@genomicprediction.com(973) 529-4223
Backup ContactDiego Marin, PhD
diego@genomicprediction.com(973) 529-4223

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026